PharmaTimes January 6, 2025
EpiSwitch PSE shows promise in reducing unnecessary procedures
Kearney Urology Center has reported a 50% reduction in biopsies since adopting EpiSwitch PSE, a new accurate blood test for prostate cancer.
The reduction is due to the test’s marked improvement over the high false positive rate of the standard prostate-specific antigen (PSA) test.
In the UK, at-risk men may be offered a PSA test, but up to three quarters of those with a high PSA do not have cancer, leading to unnecessary biopsies.
EpiSwitch PSE increases the accuracy of the PSA test from 55% to 94%, cutting false positives from 75% to just 7%. Dr Garrett Pohlman, Urologist at Kearney Urology Center, said: “I cannot imagine running my practice without EpiSwitch...
Today's Sponsors
Today's Sponsor